Our findings provide a snapshot of the current therapeutic landscape in WM after cBTKi failure. Importantly, although none of the baseline disease characteristics influenced response to cBTK‐S, the sample size is too small to make any powered evaluation. On this basis, there is an urgent need for approval in this setting. Prospective clinical trials with other targeted agents, immunotherapies, and cellular therapies are currently ongoing in cBTKi‐exposed patients to address this therapeutic gap
Salvage treatment after covalent BTKi failure: An unmet need in clinical practice in Waldenstrom macroglobulinemia
Visentin, Andrea;Ferrarini, Isacco;
2025-01-01
Abstract
Our findings provide a snapshot of the current therapeutic landscape in WM after cBTKi failure. Importantly, although none of the baseline disease characteristics influenced response to cBTK‐S, the sample size is too small to make any powered evaluation. On this basis, there is an urgent need for approval in this setting. Prospective clinical trials with other targeted agents, immunotherapies, and cellular therapies are currently ongoing in cBTKi‐exposed patients to address this therapeutic gap
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
